BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Yüksel S, Işık Gönül İ, Canpolat N, Gökçe İ, Özlü SG, Özçakar ZB, Ozaltin F, Söylemezoğlu O. Renal Biopsy Prognostic Findings in Children With Atypical Hemolytic Uremic Syndrome. Pediatr Dev Pathol 2020;23:362-71. [PMID: 32406813 DOI: 10.1177/1093526620925947] [Reference Citation Analysis]
2 Facchini L, Lucchesi M, Stival A, Roperto RM, Melosi F, Materassi M, Farina S, Tintori V, de Martino M, Sardi I. Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report. J Med Case Rep 2017;11:209. [PMID: 28747219 DOI: 10.1186/s13256-017-1373-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
3 Bicoll PS, Goyal A, Blatt NB, Freij BJ. Eculizumab-Associated Moraxella lacunata Bacteremia and Systemic Inflammatory Response Syndrome in a Toddler with Atypical Hemolytic Uremic Syndrome. Clin Med Insights Pediatr 2021;15:1179556521992367. [PMID: 33613039 DOI: 10.1177/1179556521992367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol 2017;6:4. [PMID: 28101432 DOI: 10.1186/s40164-017-0064-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
5 Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ 2022;:1-16. [PMID: 35020547 DOI: 10.1080/13696998.2022.2027706] [Reference Citation Analysis]
6 Noronha N, Costa FD, Dias A, Dinis A. Complement factor B mutation-associated aHUS and myocardial infarction. BMJ Case Rep 2017;2017:bcr-2017-219716. [PMID: 28710236 DOI: 10.1136/bcr-2017-219716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Polat M, Yüksel S, Şahin NÜ. Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab. Hum Vaccin Immunother 2018;14:2802. [PMID: 29883245 DOI: 10.1080/21645515.2018.1486157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]